Advertisement
Canada markets open in 1 minute
  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • DOW

    38,852.27
    +176.59 (+0.46%)
     
  • CAD/USD

    0.7311
    -0.0010 (-0.13%)
     
  • CRUDE OIL

    78.11
    -0.37 (-0.47%)
     
  • Bitcoin CAD

    86,889.94
    +51.21 (+0.06%)
     
  • CMC Crypto 200

    1,318.34
    -46.79 (-3.43%)
     
  • GOLD FUTURES

    2,330.20
    -1.00 (-0.04%)
     
  • RUSSELL 2000

    2,060.67
    +24.95 (+1.23%)
     
  • 10-Yr Bond

    4.4430
    -0.0460 (-1.02%)
     
  • NASDAQ futures

    18,195.25
    -0.25 (-0.00%)
     
  • VOLATILITY

    13.43
    -0.06 (-0.44%)
     
  • FTSE

    8,327.58
    +114.09 (+1.39%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6781
    -0.0011 (-0.16%)
     

Femasys Inc. to Present at The MedTech Conference

ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsick, chairman, president and chief executive officer, will participate in a presentation at The MedTech Conference. Ms. Lee-Sepsick will speak on a panel in a session, entitled, “Early-Stage Medtech and Going Public.” The MedTech Conference, an annual event powered by AdvaMed, convenes the world’s leaders in medical technology and will be held on a hybrid basis from September 21st-30th this year.

Below is the session information for “Early-Stage Medtech and Going Public”:

Date and Time: Thursday, September 30 at 10:00 a.m. – 10:35 a.m. ET

Location: Hyatt Regency Minneapolis, Great Lakes Ballroom, 1300 Nicollet Mall, Minneapolis, MN 55403

About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeedlocalized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue®, is currently marketed in the United States. Femasys is also advancing FemCerv®, a technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.

ADVERTISEMENT

Contacts:

Investors

Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com

Media
Sky Striar
LifeSci Communications
sstriar@lifescicomms.com

Femasys Inc.

Investor Contact:
IR@femasys.com

Media Contact:
Media@femasys.com